Finally, in an autologous setting, we corroborated that patient-derived iTRUCK19.18 cells exhibited enhanced efficacy in eliminating the same-patient tumor B cells only when IL-18 is induced by Dox (Figure 4E, second-right bar). Here, IL18 is linked to neoplasm.